

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

~~Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.~~

Substitute for form 1449A/PTO

Complete if Known

(Use as many sheets as necessary)

Sheet 1 of 7 Attorney Docket Number 112418.149/AUR-011

[illegible]

Examiner Signature	/Mi sook Yu/	Date Considered	07/25/2006
--------------------	--------------	-----------------	------------

"EXAMINER": Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

7

#Application Number

10/737,350

#Filing Date

12/15/2003

#First Named Inventor

Georges et al.

#Art Unit

1641

#Examiner Name

TBA

#Attorney Docket Number

112418.149/AUR-011

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
MY ↓		US- 20030012794A1	01/16/2003	Srivastava et al.	
		US- 20030031661A1	02/13/2003	Graner et al.	
		US- 20030087412A1	05/08/2003	Nandabalan et al.	
		US- 20030157081A1	08/21/2003	Bonini et al.	
		US- 20030165519A1	09/04/2003	Srivastava	
		US- 20030180721A1	09/25/2003	Witkin	
		US- 10/737,712	12/15/2003	Georges et al.	
		US- 10/736,889	12/15/2003	Georges et al.	
		US- 10/801,988	03/15/2004	Georges et al.	
		US- 5,801,154	09/01/1998	Frank et al.	
		US- 2002110912A1	08/15/2002	Jatinder et al.	
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
MY ↓		WO 02/071061A	09/12/2002	Gabor et al.		
		WO 03/008542A	01/30/2003	Scherf et al.		
		EP 0813872A	12/29/1997	Kureha Chemical		

Examiner
Signature

/Misook Yu/

Date

Considered

01/25/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/737,350
		Filing Date	12/15/2003
		First Named Inventor	Georges, et al.
		Art Unit	1641
		Examiner Name	TBA
Sheet 3 of 7	Attorney Docket Number	112418:149/AUR-011	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MY		ABOU-JAWDE et al., An Overview of Targeted Treatments in Cancer, Clinical Therapeutics, Vol. 25, No. 8, 2003, pp. 2121-2137	
		ALQAWI and GEORGES, The multidrug resistance protein ABCC1 drug-binding domains show selective sensitivity to mild detergents, Biochemical and Biophysical Research Communications 303, 2003, pp. 1135-1141	
		BARRETO et al., Stress-induced release of HSC70 from human tumors, Cellular Immunology 222, 2003, pp. 97-104	
		CHENG et al., Retaining of the Assembly Capability of Vimentin Phosphorylated by Mitogen-Activated Protein Kinase-Activated Protein Kinase-2, Journal of Cellular Biochemistry, 89, 2003, pp. 589-602	
		DEN BOER et al., Relationship Between Major Vault Protein/Lung Resistance Protein, Multidrug Resistance-Associated Protein, P-Glycoprotein Expression, and Drug Resistance in Childhood Leukemia, Blood, Vol. 91, No. 6, 1998, pp. 2092-2098	
		DI PIETRO et al., Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters, Cell. Mol. Life Sci. 59, 2002, pp. 307-322	
		DU et al., Dual Requirement for Rho and Protein Kinase C in Direct Activation of Phospholipase D1 Through G Protein-coupled Receptor Signaling, Molecular Biology of the Cell, Vol. 11, 2000, pp. 4359-4368	
		DURBIN et al., An epitope on carcinoembryonic antigen defined by the clinically relevant antibody PR1A3, Proc. Natl. Acad. Sci. USA, Vol. 91, 1994, pp. 4313-4317	
		FAIGLE et al., Vimentin Filaments in Fibroblasts Are a Reservoir for SNAP23, a Component of the Membrane Fusion Machinery, Molecular Biology of the Cell, Vol. 11, 2000, pp. 3485-3494	
		FEIG, Designer Drugs: New Directed Therapies for Cancer, International Journal of Hematology Suppl. II, 76, 2002, pp. 281-283	

Examiner Signature	/M1800K Yu/	Date Considered	07/25/2006
--------------------	-------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/737,350
		Filing Date	12/15/2003
		First Named Inventor	Georges et al.
		Art Unit	1641
		Examiner Name	TBA
Sheet 4 of 7	Attorney Docket Number	112418-149/AUR-011	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MY		FUJITA et al., High Molecular Weight Vimentin Complex Is Formed after Proteolytic Digestion of Vimentin by Caspase-3: Detection by Sera of Patients with Interstitial Pneumonia, Microbiol. Immunol., 47(6), 2003, pp. 447-451	
		GARNETT, Targeted drug conjugates: principles and progress, Advanced Drug Delivery Reviews, 53, 2001, pp. 171-216	
		GOTO et al., Phosphorylation and reorganization of vimentin by p21-activated kinase (PAK), Genes to Cells, 7, 2002, pp. 91-97	
		GRATAMA et al., Flow Cytometric Quantitation of Immunofluorescence Intensity: Problems and Perspectives, Cytometry 33, 1998, pp. 166-178	
		HEIDENTHAL et al., The Binding in Vitro of Modified LDL to the Intermediate Filament Protein Vimentin, Biochemical and Biophysical Research Communications, 267, 2000, pp. 49-53	
		HERRMANN and AEBl, Intermediate filaments and their associates: multi-talented structural elements specifying cytoarchitecture and cytodynamics, Current Opinion in Cell Biology, 12, 2000, pp. 79-90	
		HUBERT et al., STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors, PNAS, Vol. 96, No. 25, 1999, pp. 14523-14528	
		IQBAL and LENZ, Targeted Therapy and Pharmacogenomic Programs, Cancer Supplement, Vol. 97, No. 8, 2003, pp. 2076-2082	
		KIM et al., Multidrug Resistance-Associated Protein (MRP) is expressed in osteosarcoma but is not a significant mechanism of drug resistance, 47th Ann. Mtg., Orthopaedic Research Society, 2001, p. 0855	
		KIM, Targeted therapies for the treatment of cancer, The American Journal of Surgery, 186, 2003, pp. 264-268	

Examiner Signature	W. M. B. O. K. T. U. S. P. T. O.	Date Considered	07/25/2006
--------------------	----------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/737,350
		Filing Date	12/15/2003
		First Named Inventor	Georges et al
		Art Unit	1641
		Examiner Name	TBA
Sheet 5 of 7	Attorney Docket Number	112418.149/AUR-011	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MY		KOWN et al., In Vivo Imaging of Acute Cardiac Rejection in Human Patients Using 99m Technetium Labeled Annexin V, American Journal of Transplantation, 1, 2001, pp. 270-277	
		KREITMAN and PASTAN, Immunotoxins for targeted cancer therapy, Advanced Drug Delivery Reviews, 31, 1998, pp. 53-88	
		LING, Multidrug resistance: molecular mechanisms and clinical relevance, Cancer Chemother. Pharmacol., 40 Suppl., 1997, pp. S3-S8	
		MESCHINI et al., Intracellular P-glycoprotein expression is associated with the intrinsic multidrug resistance phenotype in human colon adenocarcinoma cells, Int. J. Cancer, 87, 2000, pp. 615-628	
		MOR-VAKNIN et al., Vimentin is secreted by activated macrophages, Nature Cell Biology, Vol. 5, 2003, pp. 59-63	
		PARK, Tumor-directed Targeting of Liposomes, Bioscience Reports., Vol. 22, No. 2, 2002, pp. 267-281	
		PATTERSON et al., Reduced Numatrin/B23/Nucleophosmin Labeling in Apoptotic Jurkat T-lymphoblasts, The Journal of Biological Chemistry, Vol. 270, No. 16, 1995, pp. 9429-9436	
		ROTS et al., Targeted cancer gene therapy: the flexibility of adenoviral gene therapy vectors, Journal of Controlled Release, 87, 2003, pp. 159-165	
		ROWLINSON-BUSZA and EPENETOS, Targeted delivery of biologic and other antineoplastic agents, Current Opinion in Oncology, 4, 1992, 1142-1148	
		SCHROEIJERS et al., the Mr 193,000 Vault Protein Is Up-Regulated in Multidrug-resistant Cancer Cell Lines, Cancer Research, 60, 2000, pp. 1104-1110	

Examiner Signature	/M1 Book Yu/	Date Considered	01/25/2006
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/737,350
		Filing Date	12/15/2003
		First Named Inventor	Georges et al.
		Art Unit	1641
		Examiner Name	TBA
Sheet 6 of 7	Attorney Docket Number	112418.149/AUR-011	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MY		WEHNER et al., Expression levels of hsc70 and hsp60 are developmentally regulated during B-cell maturation and not associated to childhood c-ALL at presentation or relapse, Eur. J. Haematol., 71, 2003, pp. 100-108	
		STEINERT et al., A High Molecular Weight Intermediate Filament-associated Protein in BHK-21 Cells Is Nestin, a Type VI Intermediate Filament Protein, The Journal of Biological Chemistry, Vol. 274, No. 14, 1999, pp. 9881-9890	
		STRELKOV et al., Molecular architecture of intermediate filaments, BioEssays, 25, 2003, pp. 243-251	
		TRAIL et al., Monoclonal antibody drug immunoconjugates for targeted treatment of cancer, Cancer Immunol. Immunother, 52, 2003, pp. 328-337	
		TREIB and KOTZ, Proteins expressed in osteosarcoma and serum levels as prognostic factors, The International Journal of Biochemistry & Cell Biology, 33, 2001, pp. 11-17	
		TUROWSKI et al., Vimentin Dephosphorylation by Protein Phosphatase 2A Is Modulated by the Targeting Subunit B55, Molecular Biology of the Cell, Vol. 10, 1999, pp. 1997-2015	
		WANG and LIU, Targeting Strategies in Cancer Gene Therapy, Acta Biochimica et Biophysica Sinica, 35(4), 2003, pp. 311-316	
		WU et al., High-resolution microPET imaging of carcino-embryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment, PNAS, Vol. 97, No. 15, 2000, pp. 8495-8500	
		YOKOTA et al., Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms, Cancer Research, Vol. 52, Issue 12, 1992, pp. 3402-3408	
↓		YASUAKI et al., 70 kDa heat shock cognate protein is a transformation-associated antigen and a possible target for the host's anti-tumor immunity, Journal of Immunology, Vol. 151, No. 10, 1993, pp. 5516-5524	

Examiner Signature	M. Book Yui	Date Considered	07/25/2006
--------------------	-------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

7

of

7

Complete If Known

Application Number

10/737,350

Filing Date

12/15/2003

First Named Inventor

Georges et al.

Art Unit

1641

Examiner Name

TBA

Attorney Docket Number

112418.149/AUR-011

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MY		MULTHOFF et al., A Stress-inducible 75-kDa Heat-shock Protein (HSP72) Is Expressed on the Surface of Human Tumor Cells, But Not on Normal Cells, International Journal of Cancer 1995 United States, Vol. 61, no. 2, 1995, pp. 272-279	
↓		STRIK et al., Heat Shock Protein Expression in Human Gliomas, Anticancer Research 2000 Nov.-Dec. pp. 4457-4462	
		KIANG, et al., Heat Shock Protein 70 kDa, Molecular Biology, Biochemistry, and Physiology, Pharmacology and Therapeutics, Vol. 80, no. 2, November 1998, pp. 183-201	
		VOLM, Manfred, Multidrug Resistance and Its Reversal, Anticancer Research, Vol. 18, no. 4C, July 1998, pp. 2905-2917	

Examiner
Signature

Misook Yu

Date

Considered

07/25/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/737350-Conf. #6000
				Filing Date	December 15, 2003
				First Named Inventor	Elias GEORGES
				Art Unit	2654
				Examiner Name	R. Dorvil
Sheet	1	of	1	Attorney Docket Number	0112418.00149US2/AUR-011US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ² -Number ⁴ -Kind Code ⁵ (if known)				


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
MY ↓	CA	DERMER, BioTechnology, 1994, 12:320.		
	CB	DREXLER et al., Leukemia and Lymphoma, 1993, 9:1-25.		
	CC	FRESHNEY, Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc. 1983, New York, p4.		
	CD	TOCKMAN et al., Cancer Research, 1992, 52:2711s-2718s.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Misook Yu/	Date Considered	07/25/2006
-----------------------	-------------	--------------------	------------



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/737,350	
			Filing Date	December 15, 2003	
			First Named Inventor	GEORGES et al.	
			Art Unit	1641	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	AUR-011US /112418.149US2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
MY	AA*	US-4,444,744	04-24-1984	Goldenberg, Milton	
MY	AB*	US-5,762,930	06-09-1998	Fanger et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
<div>MY</div> <div>↓</div> <div>✓</div>	CA	BICHART et al. Cytoskeleton alteration in MCF7R, a multidrug resistant human breast cancer cell line., <i>Anticancer Res.</i> , 1997, pp. 3393-401, Vol. 17.			
	CB	ESSA et al. Vimentin expression in different types of breast carinom aimmunohistochemical study, <i>J. Egypt Soc. Parasitol.</i> , 1996, pp. 433-42, Vol. 26.			
	CC	HEIDENTHAL et al. The Binding in Vitro of Modified LDL to the Intermediate Filament Protein Vimentin, <i>Biochemical and Biophysical Research Communications</i> , 2000, pp. 49-53, Vol. 267.			
	CD	MESCHINI et al. Intracellular P-Glycoprotein Expression is Associated with the Intrinsic Multidrug Resistance Phenotype in Human Colon Adenocarcinoma Cells. <i>Int. J. Cancer</i> , (2000), pp. 615-628, Vol. 87.			
	CE	THOMAS et al., Association between Keratin and Vimentin Expression, Malignant Phenotype and Survival in Postmenopausal Breast Cancer Patients, Oct. 1999, pp. 2698-2703, Vol. 5.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Misook Yu/	Date Considered	07/25/2006
-----------------------	-------------	--------------------	------------



Subt. For, PTO-1449				Docket Numbers 112418.149US2 and AUR-011US		Application Number 10/737,350	
INFORMATION DISCLOSURE IN AN APPLICATION (Use several sheets if necessary)				Applicant(s) Georges et al.			
				Filing Date December 15, 2003		Group Art Unit 1641	
Sheet	1		1				

U.S. Patent Documents				
Examiner Initial	Document Number	Publn. Date mm-dd-yyyy	Name Of Patentee Or Applicant Of Cited Documents	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear

Foreign Patent Documents					
Examiner Initial	Cite No.	Foreign Patent Document	Publn. Date mm-dd-yyyy	Country	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code-Number-Kind			
MY		DE 41 12999 A1	10/22/1992	DE	
MY		WO 02/082076 A2	10/17/2002	WIPO	

Examiner's Initial	Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)	
MY	AA	BICHART, F., et al., "Cytoskeleton Alteration in MCF7R Cells, a Multidrug Resistant Human Breast Cancer Cell Line," <i>Anticancer Research</i> , Vol. 17, pp. 3393-3402.
	AB	Database Pubmed [Online], "Triosephosphate Isomerase," US National Library of Medicine, XP002301823, Bethesda, MD, 5 January 2001.
	AC	LUDWIG, A., et al., "Identification of Differential Expressed Genes In Classical and Atypical Multidrug-resistant Gastric Carcinoma Cells," <i>Anticancer Research</i> , Vol.17, pp. 3213-3222, 1997.
	AD	MORAN E., et al., "Co-expression of MDR-Associated Markers, Including P-170, MRP and LRP and Cytoskeletal Proteins, in Three Resistant Variants of the Human Ovarian Carcinoma Cell Line, OAW42," <i>Eur J. Cancer</i> , Vol. 33, pp. 652-660, 1997.
	AE	SEKIGUCHI, M., et al., "Biological Characteristics and chemosensitivity profile of four human anaplastic thyroid carcinoma cell lines," <i>Biomed. Pharmacother</i> , Vol. 55, pp.466-474, 2001.
	AF	SWEET, P., et al., "Cyclosporin A and Verapamil Enhancement of Daunorubicin-produced Nucleolar Protein B23 Translocation in Daunorubicin-resistant and -sensitive Human and Murine Tumor Cells," <i>Cancer Research</i> , Vol. 49, pp. 677-680, 1989.
	AG	YANG, W., et al., "Multi-epitope schistosome vaccine candidates tested for protective immunogenicity in mice," <i>Vaccine</i> , Vol. 19, pp. 103-113, 2001.

EXAMINER	/Misook Yu/	DATE CONSIDERED	07/25/2006
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.			